Study following adults with obesity, diabetes or prediabetes over time
Collects health data and samples from adults with obesity, diabetes or prediabetes.
Key facts
- Who runs it
- University of California, San Francisco
- Where
- San Francisco, United StatesSee the site
- Trial code
- Registry title
- Inflammation, Diabetes, Ethnicity and Obesity Cohort
- Status
- Recruiting
- People taking part
- 350 people, planned
- Started
- Feb 2015
- Expected to end
- Dec 2029
- Type of study
- Observational
- Record updated
- 8 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 75 with a wide range of body weight and diabetes risk, including people with type 2 diabetes or metabolic syndrome. It collects data and blood, stool and fat tissue samples.
- Age
- 18 to 75 years
- Sex
- All sexes can join.
- Disease stage
- People with type 2 diabetes or the metabolic syndrome are included in the cohort. The trial recruits a wide range of body mass index (BMI) and diabetes risk.
- Earlier treatment
- People with previous bariatric surgery cannot join. People currently on chemotherapy or radiation therapy, anticoagulants, methadone or nasal corticosteroids cannot join.
Main reasons for not taking part
- Chronic kidney disease above stage 4
- Autoimmune or inflammatory disease, such as lupus or ulcerative colitis
- Clinically significant liver disease, such as cirrhosis or liver failure
- Weight above 450 pounds (204 kg), or a history of organ transplant
- Pregnant or breast-feeding women
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Participants will be healthy individuals between the ages of 18-75 years. These cutoffs are designed to allow inclusion of postmenopausal women, and younger/more active patients who are increasingly undergoing bariatric surgery
- Patients with either diabetes type 2 or the metabolic syndrome will be included in the cohort
Who cannot take part
- Treatment with chemotherapy or radiation therapy at the time of enrollment in study
- Current nasal corticosteroid use (within the past month)
- Current use of anabolic steroids or testosterone for bodybuilding purposes. Testosterone use is permitted if prescribed for hypogonadism and dose stable for the past 6 months
- Patients actively enrolled in interventional trials involving investigational agents
- Previous bariatric surgery
- Methadone medication
- Participants with chronic kidney disease (> stage 4)
- Autoimmune/inflammatory disease (e.g., Lupus, Ulcerative Colitis, etc.)
- Unstable angina, New York (NY) class III or IV congestive heart failure or myocardial infarction within 3 months of entry
- Clinically significant liver disease (e.g. Cirrhosis or liver failure)
- History of organ transplant
- History of abnormal clotting
- Weight > 450 pounds (DXA scan weight limit)
- Poorly controlled asthma (participants requiring inhaled glucocorticoids and/or oral glucocorticoids)
- Excessive alcohol or substance abuse
- Pregnant or breast-feeding women
- Appears unlikely or unable to participate in the required study procedures as assessed by the investigator, study coordinator or designee
- Anticoagulant use
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in United States
- University of California San FranciscoSan Francisco, United StatesContact: Suneil Koliwad, MD,PhDTaking people
About the trial
What the trial wants to find out
Obesity affects over one third of US adults (>72 million, with BMI ≥30 kg/m2), and the proportion of US adults with BMI ≥40 kg/m2 has doubled in the last 20 years. Obesity is associated with increased mortality through its linkage to comorbidities including diabetes, hypertension, dyslipidemia, osteoarthritis, sleep apnea and psychosocial disturbances. Given its prevalence, impact on morbidity and mortality, and economic cost, limiting the spread of obesity and its consequences is one of the most important problems of our time.
Read full original descriptionShow less
In this proposed study, investigators will recruit participants from a wide range of body mass index (BMI), ethnicity and Diabetes risk to collect data and blood, stool and adipose tissue samples in the San Francisco bay area.
The group in the trial
- IDEO Cohort
Adipose tissue samples are collected from all participants, including aspirational subcutaneous biopsies from nonsurgical participants and excisional biopsies, performed intra-operatively by surgical collaborators as required. Participants also undergo anthropometric measurements, stool collection, blood sample collection for circulating blood cells, serum, and plasma. Dual-energy x-ray absorptiometry (DXA) scan for amount and distribution of body fat as well as bone density is performed. Study participants complete validated questionnaire inventories to measure bio-behavioral issues such as depression, stress, health locus of control, and dietary habits.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Development of a Multi-Ethnic, Multimodal Obesity Cohort
- Plain-language title
- Study following adults with obesity, diabetes or prediabetes over timeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT03022682, who can take part
- Publications
- Record updated
- 8 September 2026